Dermata Therapeutics Inc
NASDAQ:DRMA

Watchlist Manager
Dermata Therapeutics Inc Logo
Dermata Therapeutics Inc
NASDAQ:DRMA
Watchlist
Price: 2.2 USD 0.92%
Market Cap: 2.3m USD

Dermata Therapeutics Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Dermata Therapeutics Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Dermata Therapeutics Inc
NASDAQ:DRMA
Net Income (Common)
-$12.3m
CAGR 3-Years
-5%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Income (Common)
$25.1B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Net Income (Common)
$6B
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Net Income (Common)
$9.8B
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Net Income (Common)
$19B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Net Income (Common)
$18.4B
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
23%
No Stocks Found

Dermata Therapeutics Inc
Glance View

Market Cap
2.3m USD
Industry
Pharmaceuticals

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate, DMT310, is a product candidate, which is developed from its Spongilla technology platform. DMT310 is a topical product derived from sourced freshwater sponge with multiple components. Its DMT310 is under clinical development for the treatment of acne vulgaris (acne), psoriasis vulgaris (psoriasis), and papulopustular rosacea (rosacea). The Company’s Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris (Spongilla). Spongilla is a freshwater sponge that grows in rivers and lakes in commercial quantities in select regions of the world, such as the northern hemisphere. Its clinical development pipeline consists of DMT310 and DMT410.

DRMA Intrinsic Value
17.54 USD
Undervaluation 87%
Intrinsic Value
Price

See Also

What is Dermata Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-12.3m USD

Based on the financial report for Dec 31, 2024, Dermata Therapeutics Inc's Net Income (Common) amounts to -12.3m USD.

What is Dermata Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-21%

Over the last year, the Net Income (Common) growth was -58%. The average annual Net Income (Common) growth rates for Dermata Therapeutics Inc have been -5% over the past three years , -21% over the past five years .

Back to Top